Skip to main content
. Author manuscript; available in PMC: 2015 Dec 1.
Published in final edited form as: Semin Oncol. 2014 Oct 7;41(6):848–859. doi: 10.1053/j.seminoncol.2014.09.013

Figure 6. The effects of selumetinib and 5-FU on tumor cell and xenograft radiosensitivity.

Figure 6

A) The HCT116 cell line was exposed to 15 μmol/L of 5-FU (or vehicle) for 18 hours and selumetinib (or vehicle) for 2 hours and irradiated with graded doses of X-rays. Colony forming efficiency was determined 10 to 12 days later and survival curves generated after normalizing for cell killing by selumetinib, 5-FU or selumetinib + 5FU in the absence of IR. B) Mice harboring HCT116 xenografts were randomized into four groups: vehicle, selumetinib, radiation + 5-FU, or selumetinib + radiation + 5-FU. Each drug was given as a single dose prior to a single dose of radiation. The study demonstrates that radiation modifiers can be evaluated in the context of chemoradiotherapy and highlights the need to account for the toxicity of both the investigational agent and chemotherapy in calculations of modifying capability. Adapted from reference (32) with permission.